PMID- 37705533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 15
DP  - 2023
TI  - Atezolizumab plus bevacizumab in patients with child-Pugh B advanced 
      hepatocellular carcinoma.
PG  - 17588359221148541
LID - 10.1177/17588359221148541 [doi]
LID - 17588359221148541
AB  - BACKGROUND: Atezolizumab plus bevacizumab (Ate/Bev) demonstrated promising 
      efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in 
      the phase III IMbrave150 trial. However, patients with Child-Pugh B HCC were 
      excluded in the abovementioned prospective trial. Therefore, we aimed to 
      investigate the efficacy and safety of Ate/Bev in patients with Child-Pugh B HCC. 
      METHODS: This multicenter retrospective study included 36 patients with 
      Child-Pugh B advanced HCC who received Ate/Bev at four cancer referral centers 
      between May 2020 and August 2021. Comparative analyses were performed with an 
      independent cohort of patients with Child-Pugh A HCC from the same registry 
      (n = 133). RESULTS: All patients received Ate/Bev as first-line systemic 
      treatment for advanced HCC. The objective response and disease control rates of 
      patients in the Child-Pugh groups B and A were 11.1% and 58.3% and 34.6% and 
      76.7%, respectively. The median progression-free survival (PFS) and overall 
      survival (OS) were 3.0 months [95% confidence interval (CI), 1.7-4.3) and 
      7.7 months (95% CI, 4.8-10.6) in the Child-Pugh B group, whereas the median PFS 
      and OS were 9.6 months (95% CI, 5.1-14.2) and not reached (95% CI, not available) 
      in the Child-Pugh A group, respectively. Compared to the Child-Pugh A group, 
      grade 3-4 adverse events (AEs) were more common in the Child-Pugh B group (44.4% 
      versus 15.8, p < 0.001), with the most frequent grade 3-4 AEs being 
      gastrointestinal bleeding (n = 6, 16.7%), neutropenia (n = 5, 13.9%), and 
      thrombocytopenia (n = 4, 11.1%). CONCLUSIONS: In the Child-Pugh B subgroup of 
      patients with advanced HCC, Ate/Bev treatment showed modest clinical activity. 
      However, due to the increased frequency of serious AEs, careful evaluation of 
      treatment response and AE management is required in this subgroup of patients.
CI  - (c) The Author(s), 2023.
FAU - Cheon, Jaekyung
AU  - Cheon J
AD  - Department of Medical Oncology, CHA Bundang Medical Center, CHA University, 
      Seongnam, South Korea.
FAU - Kim, Hyeyeong
AU  - Kim H
AD  - Department of Hematology-Oncology, Ulsan University Hospital, University of Ulsan 
      College of Medicine, Ulsan, South Korea.
FAU - Kim, Han Sang
AU  - Kim HS
AUID- ORCID: 0000-0002-6504-9927
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Kim, Chang Gon
AU  - Kim CG
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Kim, Ilhwan
AU  - Kim I
AD  - Department of Oncology, Haeundae Paik Hospital, Inje University College of 
      Medicine, Busan, South Korea.
FAU - Kang, Beodeul
AU  - Kang B
AD  - Department of Medical Oncology, CHA Bundang Medical Center, CHA University, 
      Seongnam, South Korea.
FAU - Kim, Chan
AU  - Kim C
AD  - Department of Medical Oncology, CHA Bundang Medical Center, CHA University, 
      Seongnam, South Korea.
FAU - Jung, Sanghoon
AU  - Jung S
AD  - Department Radiology, CHA Bundang Medical Center, CHA University, Seongnam, South 
      Korea.
FAU - Ha, Yeonjung
AU  - Ha Y
AD  - Department of Gastroenterology, CHA Bundang Medical Center, CHA University, 59 
      Yatap-ro, Bundang-gu, Seongnam 13496, South Korea.
FAU - Chon, Hong Jae
AU  - Chon HJ
AUID- ORCID: 0000-0002-6979-5812
AD  - Department of Medical Oncology, CHA Bundang Medical Center, CHA University, 59 
      Yatap-ro, Bundang-gu, Seongnam 13496, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20230112
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC10495918
OTO - NOTNLM
OT  - atezolizumab
OT  - bevacizumab
OT  - child-Pugh B
OT  - hepatocellular carcinoma
OT  - systemic treatment
COIS- HJC has a consulting or advisory role at Eisai, Roche, Bayer, ONO, MSD, BMS, 
      Celgene, Sanofi, Servier, AstraZeneca, Sillajen, Menarini, GreenCross Cell and 
      has received research grants from Roche, Dong-A ST, Boryung Pharmaceuticals. JC 
      received research grants from Bayer; consulting or advisory role at Roche and 
      Eisai. The other authors have no conflicts of interest to declare.
EDAT- 2023/09/14 06:42
MHDA- 2023/09/14 06:43
PMCR- 2023/01/12
CRDT- 2023/09/14 03:58
PHST- 2022/05/23 00:00 [received]
PHST- 2022/12/14 00:00 [accepted]
PHST- 2023/09/14 06:43 [medline]
PHST- 2023/09/14 06:42 [pubmed]
PHST- 2023/09/14 03:58 [entrez]
PHST- 2023/01/12 00:00 [pmc-release]
AID - 10.1177_17588359221148541 [pii]
AID - 10.1177/17588359221148541 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2023 Jan 12;15:17588359221148541. doi: 
      10.1177/17588359221148541. eCollection 2023.